Literature DB >> 11251967

The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines.

K Dohmoto1, S Hojo, J Fujita, Y Yang, Y Ueda, S Bandoh, Y Yamaji, Y Ohtsuki, N Dobashi, T Ishida, J Takahara.   

Abstract

The CYFRA 21-1 assay, which detects cytokeratin 19 (CK19) fragment, is widely used as a tumor marker for lung cancer, particularly non-small cell lung cancer. However, the reason that some lung cancer cell lines release CYFRA 21-1 in culture supernatants and others do not remains unclear. We hypothesized that the release of CYFRA 21-1 might be related to the expression of CK19 and caspase 3. In order to prove this, the quantities of mRNA for CK19 were evaluated by the competitive reverse transcriptase-polymerase chain reaction (RT-PCR). CK19 protein synthesis was also evaluated by Western blotting and immunohistochemistry, and the levels of CYFRA 21-1 in the culture supernatant were measured by an immunoradiometric assay. The expression of mRNA for caspase 3 was evaluated by the RT-PCR, and caspase 3 protein synthesis was also evaluated by immunohistochemistry. In 13 lung cancer cell lines, the amounts of mRNA for CK19 correlated with the levels of CYFRA 21-1 in culture supernatants, results of Western blotting for CK19, and positivities of immunohistochemistry for CK19. In 5 cell lines that produced a significant amount of CYFRA 21-1, the level of CYFRA 21-1 correlated with the positivity of RT-PCR for caspase 3 and immunohistochmistry for caspase 3. This suggests that caspase 3 played a role in the formation of CYFRA 21-1. In addition, the specific inhibitor of caspase 3 significantly inhibited the release of CYFRA 21-1 in culture supernatants. In conclusion, we demonstrate that caspase 3, which cleaves several intermediate filaments and carries out cell apoptosis, played an important role in producing CYFRA 21-1 in human lung cancer cell lines. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251967     DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1082>3.0.co;2-t

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  A Strong Neutrophil Elastase Proteolytic Fingerprint Marks the Carcinoma Tumor Proteome.

Authors:  Michał Kistowski; Janusz Dębski; Jakub Karczmarski; Agnieszka Paziewska; Jacek Olędzki; Michał Mikula; Jerzy Ostrowski; Michał Dadlez
Journal:  Mol Cell Proteomics       Date:  2016-12-07       Impact factor: 5.911

2.  Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study.

Authors:  Xin Wang; Xiuyi Zhi; Yi Zhang; Guangyu An; Guosheng Feng
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Age and Smoking Status Affect Serum Cytokeratin 19 Fragment Levels in Individuals Without Cancer.

Authors:  Asami Minamibata; Yoshihito Kono; Taichiro Arimoto; Yoshinori Marunaka; Koichi Takayama
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

4.  Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Li Huang; Wei Chen; Peiwen Liang; Wenjie Hu; Kunsong Zhang; Shunli Shen; Jiancong Chen; Zhaohui Zhang; Bin Chen; Yuyan Han; Fanyin Meng; Sharon DeMorrow; Xiaoyu Yin; Jiaming Lai; Lijian Liang
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

5.  Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours.

Authors:  Renee G H M van Sprundel; Ted S G A M van den Ingh; Valeer J Desmet; Azeam Katoonizadeh; Louis C Penning; Jan Rothuizen; Tania Roskams; Bart Spee
Journal:  Comp Hepatol       Date:  2010-02-18

6.  Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma.

Authors:  Rewa Malhotra; Aadithya B Urs; Anita Chakravarti; Suman Kumar; V K Gupta; Bhawna Mahajan
Journal:  Tumour Biol       Date:  2016-01-15

7.  Circulating cytokeratin 18 fragments and activation of dormant tumor cells in bone marrow of cancer patients.

Authors:  Christoph Ausch; Veronika Buxhofer-Ausch; Ulrike Olszewski; Gerhard Hamilton
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

8.  Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries.

Authors:  Mariana Guergova-Kuras; István Kurucz; William Hempel; Nadège Tardieu; János Kádas; Carole Malderez-Bloes; Anne Jullien; Yann Kieffer; Marina Hincapie; András Guttman; Eszter Csánky; Balázs Dezso; Barry L Karger; László Takács
Journal:  Mol Cell Proteomics       Date:  2011-09-26       Impact factor: 5.911

9.  Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.

Authors:  J Cummings; M Ranson; E Lacasse; J R Ganganagari; M St-Jean; G Jayson; J Durkin; C Dive
Journal:  Br J Cancer       Date:  2006-07-03       Impact factor: 7.640

10.  Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.

Authors:  T Uenishi; S Kubo; K Hirohashi; H Tanaka; T Shuto; T Yamamoto; S Nishiguchi
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.